Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placulumab
- Development stage
- Phase 2
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous (investigational)
01
Overview
Placulumab is a fully human monoclonal antibody that targets and neutralizes tumor necrosis factor alpha (TNF-α), a key pro-inflammatory cytokine. It was developed as an anti-inflammatory biologic for the treatment of inflammatory diseases such as rheumatoid arthritis and sciatica. Placulumab acts by binding to TNF-α and inhibiting its interaction with TNF receptors, thereby reducing inflammation and immune-mediated tissue damage. The drug was originally developed by Domantis and Peptech, later advanced by Arana Therapeutics and Teva Pharmaceutical Industries. Despite early clinical trials in conditions like rheumatoid arthritis, psoriasis, and sciatica, development of placulumab has been discontinued[2][3][4][5][9].
- Other names
- placulumabanti-TNF alpha antibodyanti-tumour necrosis factor alpha antibody
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on placulumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placulumab.